Lymphoma, T-Cell, Peripheral: all 607 studies

Page 1 of 7. Open to participants first (133), then studies with results posted, then the rest; newest registration first within each.

• Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)AvailableNCT07862465
• Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.Not yet recruitingNCT07842445Phase 1
• Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)RecruitingNCT07750886
• The Efficacy of CAPCT in Patients With PTCLNot yet recruitingNCT07746245Phase 2
• Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaRecruitingNCT07730515Phase 1/2
• Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)Not yet recruitingNCT07729397Phase 1
• New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingNCT07706959Phase 1/2
• A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.Not yet recruitingNCT07657572
• Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in SpainRecruitingNCT07624838
• Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell LymphomaNot yet recruitingNCT07615283Phase 1/2
• Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell LymphomaNot yet recruitingNCT07535762Phase 2
• Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
• T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NRRecruitingNCT07470996
• Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line ChemotherapyRecruitingNCT07414758Phase 3
• A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell LymphomaRecruitingNCT07389616Phase 2/3
• Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 1
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 2
• T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CRRecruitingNCT07353840
• Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingNCT07300514Phase 3
• Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingNCT07288814Phase 1/2
• Amping up With PemJAKRecruitingNCT07283822Phase 2
• Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingNCT07279584Phase 2
• Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort StudyRecruitingNCT07270861
• BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationNCT07258680Phase 3
• Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)RecruitingNCT07253129
• A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingNCT07234162Phase 3
• Karyopharm Expanded Access Program for SelinexorAvailableNCT07215832
• Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07209163Phase 1/2
• A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT07195916Phase 1
• A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 1
• A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.Not yet recruitingNCT07180771Phase 2
• Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell LymphomaRecruitingNCT07164560Phase 1
• Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaRecruitingNCT07162012Early Phase 1
• Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT07093710Phase 1/2
• Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.Not yet recruitingNCT07081607Phase 2
• Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL PatientsRecruitingNCT07072221Not applicable
• Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Not yet recruitingNCT07032532Phase 2
• A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaRecruitingNCT07000617Phase 2
• A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingNCT06966154Phase 1/2
• A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell LymphomaNot yet recruitingNCT06963632
• A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.Not yet recruitingNCT06953739Phase 3
• Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT06947967Phase 3
• CD7 CAR T-Cell Therapy for r/r T-cell LymphomasRecruitingNCT06925464Phase 1/2
• A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesRecruitingNCT06914037Phase 1
• Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT06909877Phase 1/2
• A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCLRecruitingNCT06855823Phase 1/2
• Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaRecruitingNCT06824883Phase 2
• Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06793956Phase 1
• A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT06776952Phase 3
• Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
• Golidocitinib Plus CHOP in Newly Diagnosed PTCLRecruitingNCT06739265Phase 1/2
• Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
• Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT06712173Phase 1
• To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaNot yet recruitingNCT06702605Phase 2
• Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingNCT06701344Phase 2
• Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell LymphomaNot yet recruitingNCT06671717Not applicable
• A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingNCT06630091Phase 2
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaRecruitingNCT06561048Phase 3
• A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell LymphomaNot yet recruitingNCT06548347Phase 2/3
• A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 3
• Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingNCT06519526Phase 2
• Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 1
• RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.RecruitingNCT06468267Phase 2
• A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaRecruitingNCT06436677
• CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaRecruitingNCT06433362Phase 2
• Linperlisib Combined With Chidamide in Patients With PTCLRecruitingNCT06421948Phase 1/2
• Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T CellsRecruitingNCT06420076Phase 1/2
• Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTLRecruitingNCT06406556Phase 2
• A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune SystemNot yet recruitingNCT06385522Phase 1
• Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLRecruitingNCT06382844
• Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingNCT06376721Phase 1/2
• The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell LymphomaNot yet recruitingNCT06255795Phase 3
• GVM±R in Patients With Relapsed or Refractory Aggressive NHL.RecruitingNCT06244368Phase 2
• Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITLRecruitingNCT06224842Phase 1/2
• Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-TRecruitingNCT06224049Early Phase 1
• Chi-GVM Regimen for the Treatment of R/R PTCLRecruitingNCT06211881Not applicable
• Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasRecruitingNCT06176690Phase 1
• Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell LymphomasRecruitingNCT06176027Phase 1/2
• A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell LymphomaRecruitingNCT06173999Phase 1/2
• Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell LymphomaRecruitingNCT06160843Phase 2
• Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell LymphomaRecruitingNCT06151106Phase 2
• AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center StudyRecruitingNCT06083701Phase 1/2
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center StudyRecruitingNCT06037239Phase 1/2
• Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell LymphomaNot yet recruitingNCT05979792Early Phase 1
• Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05976997Phase 2
• Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingNCT05958719Phase 2
• Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaRecruitingNCT05941156Phase 2
• Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)RecruitingNCT05934864
• A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05934513Phase 1/2
• A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCLRecruitingNCT05931263Phase 3
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingNCT05900089Phase 1
• CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaRecruitingNCT05896813Not applicable
• Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell LymphomaRecruitingNCT05833893Phase 2
• Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)RecruitingNCT05833724Phase 2
• AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFHEnrolling by invitationNCT05678933Phase 3

← Lymphoma, T-Cell, Peripheral overview